全文获取类型
收费全文 | 8920篇 |
免费 | 767篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 225篇 |
妇产科学 | 249篇 |
基础医学 | 1184篇 |
口腔科学 | 152篇 |
临床医学 | 979篇 |
内科学 | 1435篇 |
皮肤病学 | 135篇 |
神经病学 | 554篇 |
特种医学 | 627篇 |
外科学 | 1130篇 |
综合类 | 324篇 |
一般理论 | 3篇 |
预防医学 | 855篇 |
眼科学 | 232篇 |
药学 | 590篇 |
2篇 | |
中国医学 | 36篇 |
肿瘤学 | 937篇 |
出版年
2022年 | 70篇 |
2021年 | 132篇 |
2020年 | 75篇 |
2019年 | 109篇 |
2018年 | 125篇 |
2017年 | 110篇 |
2016年 | 95篇 |
2015年 | 130篇 |
2014年 | 205篇 |
2013年 | 292篇 |
2012年 | 375篇 |
2011年 | 386篇 |
2010年 | 275篇 |
2009年 | 257篇 |
2008年 | 361篇 |
2007年 | 376篇 |
2006年 | 395篇 |
2005年 | 333篇 |
2004年 | 357篇 |
2003年 | 353篇 |
2002年 | 316篇 |
2001年 | 280篇 |
2000年 | 270篇 |
1999年 | 281篇 |
1998年 | 166篇 |
1997年 | 151篇 |
1996年 | 135篇 |
1995年 | 126篇 |
1994年 | 97篇 |
1993年 | 99篇 |
1992年 | 151篇 |
1991年 | 188篇 |
1990年 | 174篇 |
1989年 | 171篇 |
1988年 | 175篇 |
1987年 | 181篇 |
1986年 | 152篇 |
1985年 | 187篇 |
1984年 | 119篇 |
1983年 | 117篇 |
1982年 | 69篇 |
1981年 | 66篇 |
1980年 | 72篇 |
1979年 | 93篇 |
1978年 | 70篇 |
1977年 | 69篇 |
1976年 | 60篇 |
1975年 | 61篇 |
1973年 | 70篇 |
1972年 | 58篇 |
排序方式: 共有9745条查询结果,搜索用时 15 毫秒
11.
Robert C Susil Kevin Camphausen Peter Choyke Elliot R McVeigh Gary S Gustafson Holly Ning Robert W Miller Ergin Atalar C Norman Coleman Cynthia Ménard 《Magnetic resonance in medicine》2004,52(3):683-687
A technique for transperineal high-dose-rate (HDR) prostate brachytherapy and needle biopsy in a standard 1.5 T MRI scanner is demonstrated. In each of eight procedures (in four patients with intermediate to high risk localized prostate cancer), four MRI-guided transperineal prostate biopsies were obtained followed by placement of 14-15 hollow transperineal catheters for HDR brachytherapy. Mean needle-placement accuracy was 2.1 mm, 95% of needle-placement errors were less than 4.0 mm, and the maximum needle-placement error was 4.4 mm. In addition to guiding the placement of biopsy needles and brachytherapy catheters, MR images were also used for brachytherapy treatment planning and optimization. Because 1.5 T MR images are directly acquired during the interventional procedure, dependence on deformable registration is reduced and online image quality is maximized. 相似文献
12.
Gary Coleman Tom A. Gardiner Ariel Boutaud Alan W. Stitt 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2007,245(4):581-587
Background A recombinant form of the α2(IV)NC1 domain of type IV collagen has been shown to have potent anti-angiogenic activity although
this peptide has not been studied in the context of proliferative retinopathies. In the current investigation we examined
the potential for α2(IV)NC1 to regulate retinal microvascular endothelial cell function using a range of in vitro and in vivo
assay systems.
Materials and methods α2(IV)NC1 at concentrations between 0.1 and 1 μg/ml was added to retinal microvascular endothelial cells (RMECs) followed
by assessment of cell attachment, proliferation and survival. This agent was also tested within a novel in vitro three-dimensional
retinal angiogenesis assay and the number of angiogenic sprouts quantified. α2(IV)NC1 was also delivered intra-vitreally to
mice with oxygen-induced proliferative retinopathy (OIR) and neovascularisation evaluated in comparison with vehicle-treated
controls.
Results RMECs treated with α2(IV)NC1 (0.1, 0.5 and 1 μg/ml) showed delayed attachment at 3 h post-seeding, although this deficit had
been restored at the 6-h time point. BrdU assay of DNA replication revealed that confluent RMECs treated with α2(IV)NC1 showed
no measurable response in comparison with vehicle-treated controls. By contrast, proliferation of sub-confluent RMECs was
significantly reduced by α2(IV)NC1 at 0.5 μg/ml (P<0.01). α2(IV)NC1 also induced apoptosis in RMECs and inhibited angiogenesis of pre-existing retinal vascular networks in
vitro (P<0.001). Intra-vitreal injection of α2(IV)NC1 in the OIR model significantly inhibited pre-retinal neovascularisation compared
with vehicle-treated controls (P<0.001).
Conclusion α2(IV)NC1 inhibits angiogenesis in the retinal microvasculature. This recombinant protein has potential for the treatment
of neovascularisation in proliferative retinopathies.
BioStratum Inc. did not sponsor this research in any way. None of the authors are paid consultants with this company. 相似文献
13.
Michael R Zalutsky David A Reardon Gamal Akabani R Edward Coleman Allan H Friedman Henry S Friedman Roger E McLendon Terence Z Wong Darell D Bigner 《Journal of nuclear medicine》2008,49(1):30-38
alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors. The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors. METHODS: Chimeric antitenascin monoclonal antibody 81C6 (ch81C6) (10 mg) was labeled with 71-347 MBq of (211)At by use of N-succinimidyl 3-[(211)At]astatobenzoate. Eighteen patients were treated with (211)At-labeled ch81C6 ((211)At-ch81C6) administered into a surgically created resection cavity (SCRC) and then with salvage chemotherapy. Serial gamma-camera imaging and blood sampling over 24 h were performed. RESULTS: A total of 96.7% +/- 3.6% (mean +/- SD) of (211)At decays occurred in the SCRC, and the mean blood-pool percentage injected dose was < or = 0.3. No patient experienced dose-limiting toxicity, and the maximum tolerated dose was not identified. Six patients experienced grade 2 neurotoxicity within 6 wk of (211)At-ch81C6 administration; this neurotoxicity resolved fully in all but 1 patient. No toxicities of grade 3 or higher were attributable to the treatment. No patient required repeat surgery for radionecrosis. The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively. CONCLUSION: This study provides proof of concept for regional targeted radiotherapy with (211)At-labeled molecules in oncology. Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors. 相似文献
14.
Susannah V Quisling Vinay A Shah Ho K Lee Bruno Policeni Wendy R K Smoker Coleman Martin Andrew G Lee 《Journal of neuro-ophthalmology》2006,26(1):47-48
A 44-year-old man with right-sided herpes zoster ophthalmicus (HZO) developed ipsilateral third and sixth cranial nerve palsies and first-division trigeminal (fifth cranial nerve) sensory loss. MRI revealed contrast enhancement of the cisternal and cavernous portions of the third cranial nerve and high signal on a FLAIR sequence within the ipsilateral medulla at the presumed location of the trigeminal nucleus and tract. To our knowledge, this is the first report of the combination of these imaging findings in HZO. 相似文献
15.
16.
17.
18.
Scoring manual for the Thought Disorder Index 总被引:1,自引:0,他引:1
19.
20.
DA Taylor 《Environmental health perspectives》2002,110(9):A512-A513